Patents by Inventor Diane Barbara Hauze

Diane Barbara Hauze has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gonadotropin releasing hormone receptor antagonists
    Patent number: 7696210
    Abstract: Compounds of Formula I, useful as Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists, are disclosed.
    Type: Grant
    Filed: June 16, 2005
    Date of Patent: April 13, 2010
    Assignee: Wyeth
    Inventors: Lloyd Michael Garrick, Daniel Michael Green, Diane Barbara Hauze, Kenneth Lewis Kees, Joseph Theodore Lundquist, IV, Charles William Mann, John Francis Mehlmann, Jeffrey Claude Pelletier, John Francis Rogers, Jr., Jay Edward Wrobel
  • TRIFLUOROMETHYL-CONTAINING PHENYLSULFONAMIDE BETA AMYLOID INHIBITORS
    Publication number: 20090221711
    Abstract: A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R1-R7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.
    Type: Application
    Filed: May 12, 2009
    Publication date: September 3, 2009
    Applicant: Wyeth
    Inventors: Alexander Michael Porte, Thomas Joseph Caggiano, George Diamantidis, Diane Barbara Hauze, Boyd Lynn Harrison, Molly Hoke, Anthony Kreft, Dennis M. Kubrak, Charles William Mann, Scott Mayer, Koi Michele Morris
  • Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
    Patent number: 7550629
    Abstract: A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R1-R7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: June 23, 2009
    Assignee: Wyeth
    Inventors: Alexander Michael Porte, Thomas Joseph Caggiano, George Diamantidis, Diane Barbara Hauze, Boyd Lynn Harrison, Molly Hoke, Anthony Kreft, Dennis M. Kubrak, Charles William Mann, Scott Mayer, Koi Michele Morris
  • NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM
    Publication number: 20090054392
    Abstract: The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-?-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog.
    Type: Application
    Filed: August 19, 2008
    Publication date: February 26, 2009
    Applicant: Wyeth
    Inventors: Jeffrey Claude Pelletier, Luciana de Araujo Felix, Daniel Michael Green, Diane Barbara Hauze, Joseph Theodore Lundquist, IV, Charles William Mann, John Francis Mehlmann, John Francis Rogers, JR., Matthew Douglas Vera, Albert John Molinari
  • PYRIMIDINE SULFONAMIDE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM
    Publication number: 20090048282
    Abstract: The present invention relates to pyrimidine sulfonamide analogs, methods of making pyrimidine sulfonamide analogs, compositions comprising a pyrimidine sulfonamide analog, and methods for treating canonical Wnt-?-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a pyrimidine sulfonamide analog.
    Type: Application
    Filed: August 14, 2008
    Publication date: February 19, 2009
    Applicant: Wyeth
    Inventors: Diane Barbara Hauze, Matthew Gregory Bursavich, Luciana de Araujo Felix, Adam Matthew Gilbert, Jeffrey Claude Pelletier
  • HETEROARYL/ARYL PYRIMIDINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM
    Publication number: 20080287452
    Abstract: The present invention relates to heteroaryl/aryl pyrimidine analogs, methods of making aryl/heteroaryl pyrimidine analogs, compositions comprising a aryl/heteroaryl pyrimidine analog, and methods for treating canonical Wnt-?-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a heteroaryl/aryl pyrimidine analog.
    Type: Application
    Filed: May 16, 2008
    Publication date: November 20, 2008
    Applicant: Wyeth
    Inventors: Matthew Gregory BURSAVICH, Adam Matthew GILBERT, Diane Barbara HAUZE, Charles William MANN, Jeffrey Claude PELLETIER
  • Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
    Publication number: 20070249722
    Abstract: A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R1-R7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.
    Type: Application
    Filed: April 19, 2007
    Publication date: October 25, 2007
    Applicant: Wyeth
    Inventors: Alexander Michael Porte, Thomas Joseph Caggiano, George Diamantidis, Diane Barbara Hauze, Boyd Lynn Harrison, Molly Hoke, Anthony Kreft, Dennis M. Kubrak, Charles William Mann, Scott Mayer, Koi Michele Morris
  • Bicyclic antagonists selective for the &agr;v&bgr;3 integrin
    Patent number: 6429214
    Abstract: This invention provides novel bicyclic compounds of Formula (I): wherein u, v, m, Y, G, A—B, R1, R1a, R2, R4, R5, R5a, and R5b are defined in the specification which compounds exhibit activity as inhibitors of bone resorption and compounds of Formula (II) wherein u, v, m, Y, G, D, A—B, R1, R1a, R2, R3, R4, R5, R5a, and R5b are defined in the specification which compounds exhibit activity as inhibitors of bone resorption.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: August 6, 2002
    Assignee: Wyeth
    Inventors: Arie Zask, Diane Barbara Hauze, Kenneth Lewis Kees, Richard Dale Coghlan, John Yardley